Abstract 13219: Prognostic Value of Direct Bilirubin in Acute Decompensated Heart Failure

Atsushi Okada(National Cerebral and Cardiovascular Center), Toshihisa Anzai(Hokkaido University), Kenji Nakamura(Chiba University), Tatsuhiro Shibata(United Cerebral Palsy), Satoshi Yasuda(Tohoku University), Takeshi Aiba(National Cerebral and Cardiovascular Center), Hisao Ogawa(Kumamoto University Hospital), Takafumi Yamane, Teruo Noguchi(National Cerebral and Cardiovascular Center), Yasuhide Asaumi(National Cerebral and Cardiovascular Center), Kengo Kusano(Northwestern University), Masaharu Ishihara(Hyogo Medical University), Naotsugu Iwakami(Kyoto University), Daigo Chinen, Toshiyuki Nagai(Hokkaido University), Yasuo Sugano(keiyu Hospital)
Circulation
November 25, 2014
Cited by 0

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755